| type |
entity_type |
name |
domain |
status |
founded |
headquarters |
funding |
key_people |
tags |
supports |
reweave_edges |
| entity |
company |
Telegra |
health |
active |
|
|
|
|
| telehealth |
| medical-groups |
| GLP-1 |
| prescribing-infrastructure |
|
| FDA GLP-1 telehealth warning letters target a concentrated network where 30+ percent of warned firms affiliate with just four medical groups, making regulatory action on four organizations potentially market-transforming |
|
| FDA GLP-1 telehealth warning letters target a concentrated network where 30+ percent of warned firms affiliate with just four medical groups, making regulatory action on four organizations potentially market-transforming|supports|2026-05-13 |
|
Telegra
Overview
Telegra is one of four nationwide medical groups providing prescribing infrastructure for GLP-1 telehealth platforms. STAT News investigation (March 2026) identified Telegra as part of a concentrated network supporting at least 30% of telehealth firms that received FDA warning letters for misleading GLP-1 marketing.
Business Model
Provides affiliated clinician services for telehealth platforms. The business model separates marketing (telehealth platform) from prescribing (medical group), creating accountability gaps where neither entity takes full responsibility for the patient journey.
Regulatory Context
FDA warning letters (March 2026) targeted telehealth marketing firms, not the affiliated medical groups directly. However, the concentrated network structure (4 groups supporting 30%+ of warned firms) creates regulatory leverage point.
Timeline
- 2026-03-12 — Identified by STAT News as one of four medical groups affiliated with 30%+ of FDA-warned GLP-1 telehealth firms
Sources
- STAT News investigation, March 12, 2026
